Cell Therapeutics (CTIC) to Meet with FDA Over Pixantrone NDA Submission
Tweet
Share
E-mail
Cell Therapeutics, Inc. (Nasdaq: CTICD)(Nasdaq: CTIC) reports that it will meet with the U.S. Food and Drugs Administration's Office of Oncology Drug Products in early June to discuss the re-submission of CTI's New Drug Application for pixantrone for accelerated approval to treat patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Boeing names Ryan Shedd as new SVP and controller
- loanDepot receives NYSE non-compliance notice over stock price
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
